Used in positron emission tomography (PET) imaging to detect beta-amyloid plaques in the brain, flobetapir helps in the evaluation of Alzheimer's disease. It binds to amyloid deposits, allowing clinicians to visualize plaque distribution and density. This aids in differential diagnosis, especially in patients with cognitive impairment, and supports clinical decision-making regarding disease progression and treatment strategies. Its imaging capability is valuable in both research and clinical settings for assessing amyloid burden.